MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

Dario Zimmerli(The Netherlands Cancer Institute), Jos Jonkers(The Netherlands Cancer Institute)

Nature Communications

November 2, 2022

10.1038/s41467-022-34000-6

Cited by 130

Related Papers

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

|Nature Structural & Molecular Biology|2010|1k

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers

|Nature|2022|130

CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer

|Nature Communications|2023|112

Functional Categorization of <i>BRCA1</i> Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays

|Clinical Cancer Research|2020|39

A living biobank of patient-derived ductal carcinoma in situ mouse-intraductal xenografts identifies risk factors for invasive progression

|Cancer Cell|2023|39